Serum HBcrAg and Hepatocellular Carcinoma in a Taiwanese Population Seronegative for HBsAg and Anti-HCV

Yi Chung Hsieh; Mei Hung Pan; Wen Juei Jeng; Hui Han Hu; Jessica Liu; Masashi Mizokami; Chien Jen Chen; Hwai I. Yang

doi:10.1016/j.cgh.2022.06.018

Serum HBcrAg and Hepatocellular Carcinoma in a Taiwanese Population Seronegative for HBsAg and Anti-HCV

Yi Chung Hsieh, Mei Hung Pan, Wen Juei Jeng^*, Hui Han Hu, Jessica Liu, Masashi Mizokami, Chien Jen Chen, Hwai I. Yang^*

^*此作品的通信作者

醫學系

研究成果: 期刊稿件 › 文章 › 同行評審

7 引文斯高帕斯（Scopus）

摘要

BACKGROUND & AIMS: Hepatitis B core-related antigen (HBcrAg) is a surrogate seromarker of intrahepatic hepatitis B virus covalently closed circular DNA quantity and activity and a predictor of hepatocellular carcinoma (HCC) in chronic hepatitis B patients. We assess association between HBcrAg and HCC in individuals seronegative for hepatitis B surface antigen and anti-hepatitis C virus (NBNC) in Taiwan.

METHODS: A total of 129 newly developed HCC cases and 520 frequency-matched non-HCC controls were drawn from the REVEAL-NBNC cohort. Serum HBcrAg and other risk factors measured at recruitment were compared between cases and controls. Regression analysis was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs).

RESULTS: The proportion of baseline HBcrAg positivity (≥1000 U/mL) was significantly higher in HCC cases than in controls (12.4% vs 1.4%, P < .001). In multivariate analysis, HBcrAg positivity was associated with significantly higher risk of HCC (adjusted OR [95% CI]: 9.3 [3.3-26.4]; P < .001]. The HCC population attributable to HBcrAg positivity was 11.1% (95% CI: 9.7%-12.5%).

CONCLUSIONS: Seropositivity of HBcrAg might identify a subset of the NBNC population at higher risk of HCC in hepatitis B virus endemic areas.

原文	英語
頁（從 - 到）	1303-1313.e11
期刊	Clinical Gastroenterology and Hepatology
卷	21
發行號	5
DOIs	https://doi.org/10.1016/j.cgh.2022.06.018
出版狀態	已出版 - 05 2023

文獻附註

UN SDG

此研究成果有助於以下永續發展目標

存取文件

10.1016/j.cgh.2022.06.018

其它文件與鏈接

Link to publication in Scopus

引用此

@article{dc43a45bd7d2443294b507b831f24349,

title = "Serum HBcrAg and Hepatocellular Carcinoma in a Taiwanese Population Seronegative for HBsAg and Anti-HCV",

abstract = "BACKGROUND & AIMS: Hepatitis B core-related antigen (HBcrAg) is a surrogate seromarker of intrahepatic hepatitis B virus covalently closed circular DNA quantity and activity and a predictor of hepatocellular carcinoma (HCC) in chronic hepatitis B patients. We assess association between HBcrAg and HCC in individuals seronegative for hepatitis B surface antigen and anti-hepatitis C virus (NBNC) in Taiwan.METHODS: A total of 129 newly developed HCC cases and 520 frequency-matched non-HCC controls were drawn from the REVEAL-NBNC cohort. Serum HBcrAg and other risk factors measured at recruitment were compared between cases and controls. Regression analysis was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs).RESULTS: The proportion of baseline HBcrAg positivity (≥1000 U/mL) was significantly higher in HCC cases than in controls (12.4% vs 1.4%, P < .001). In multivariate analysis, HBcrAg positivity was associated with significantly higher risk of HCC (adjusted OR [95% CI]: 9.3 [3.3-26.4]; P < .001]. The HCC population attributable to HBcrAg positivity was 11.1% (95% CI: 9.7%-12.5%).CONCLUSIONS: Seropositivity of HBcrAg might identify a subset of the NBNC population at higher risk of HCC in hepatitis B virus endemic areas.",

keywords = "Non-Hepatitis B, Non-Hepatitis C, Nonalcoholic Fatty Liver Disease, Occult HBV, Hepatitis B, Chronic, Humans, Liver Neoplasms/epidemiology, Hepatitis B Surface Antigens, Hepatitis B Core Antigens, DNA, Circular, Biomarkers, Carcinoma, Hepatocellular/epidemiology, DNA, Viral, Hepatitis B virus/genetics",

author = "Hsieh, {Yi Chung} and Pan, {Mei Hung} and Jeng, {Wen Juei} and Hu, {Hui Han} and Jessica Liu and Masashi Mizokami and Chen, {Chien Jen} and Yang, {Hwai I.}",

year = "2023",

month = may,

doi = "10.1016/j.cgh.2022.06.018",

language = "英语",

volume = "21",

pages = "1303--1313.e11",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders",

number = "5",

}

TY - JOUR

T1 - Serum HBcrAg and Hepatocellular Carcinoma in a Taiwanese Population Seronegative for HBsAg and Anti-HCV

AU - Hsieh, Yi Chung

AU - Pan, Mei Hung

AU - Jeng, Wen Juei

AU - Hu, Hui Han

AU - Liu, Jessica

AU - Mizokami, Masashi

AU - Chen, Chien Jen

AU - Yang, Hwai I.

PY - 2023/5

Y1 - 2023/5

N2 - BACKGROUND & AIMS: Hepatitis B core-related antigen (HBcrAg) is a surrogate seromarker of intrahepatic hepatitis B virus covalently closed circular DNA quantity and activity and a predictor of hepatocellular carcinoma (HCC) in chronic hepatitis B patients. We assess association between HBcrAg and HCC in individuals seronegative for hepatitis B surface antigen and anti-hepatitis C virus (NBNC) in Taiwan.METHODS: A total of 129 newly developed HCC cases and 520 frequency-matched non-HCC controls were drawn from the REVEAL-NBNC cohort. Serum HBcrAg and other risk factors measured at recruitment were compared between cases and controls. Regression analysis was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs).RESULTS: The proportion of baseline HBcrAg positivity (≥1000 U/mL) was significantly higher in HCC cases than in controls (12.4% vs 1.4%, P < .001). In multivariate analysis, HBcrAg positivity was associated with significantly higher risk of HCC (adjusted OR [95% CI]: 9.3 [3.3-26.4]; P < .001]. The HCC population attributable to HBcrAg positivity was 11.1% (95% CI: 9.7%-12.5%).CONCLUSIONS: Seropositivity of HBcrAg might identify a subset of the NBNC population at higher risk of HCC in hepatitis B virus endemic areas.

AB - BACKGROUND & AIMS: Hepatitis B core-related antigen (HBcrAg) is a surrogate seromarker of intrahepatic hepatitis B virus covalently closed circular DNA quantity and activity and a predictor of hepatocellular carcinoma (HCC) in chronic hepatitis B patients. We assess association between HBcrAg and HCC in individuals seronegative for hepatitis B surface antigen and anti-hepatitis C virus (NBNC) in Taiwan.METHODS: A total of 129 newly developed HCC cases and 520 frequency-matched non-HCC controls were drawn from the REVEAL-NBNC cohort. Serum HBcrAg and other risk factors measured at recruitment were compared between cases and controls. Regression analysis was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs).RESULTS: The proportion of baseline HBcrAg positivity (≥1000 U/mL) was significantly higher in HCC cases than in controls (12.4% vs 1.4%, P < .001). In multivariate analysis, HBcrAg positivity was associated with significantly higher risk of HCC (adjusted OR [95% CI]: 9.3 [3.3-26.4]; P < .001]. The HCC population attributable to HBcrAg positivity was 11.1% (95% CI: 9.7%-12.5%).CONCLUSIONS: Seropositivity of HBcrAg might identify a subset of the NBNC population at higher risk of HCC in hepatitis B virus endemic areas.

KW - Non-Hepatitis B

KW - Non-Hepatitis C

KW - Nonalcoholic Fatty Liver Disease

KW - Occult HBV

KW - Hepatitis B, Chronic

KW - Humans

KW - Liver Neoplasms/epidemiology

KW - Hepatitis B Surface Antigens

KW - Hepatitis B Core Antigens

KW - DNA, Circular

KW - Biomarkers

KW - Carcinoma, Hepatocellular/epidemiology

KW - DNA, Viral

KW - Hepatitis B virus/genetics

UR - http://www.scopus.com/inward/record.url?scp=85139730142&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2022.06.018

DO - 10.1016/j.cgh.2022.06.018

M3 - 文章

C2 - 35850414

AN - SCOPUS:85139730142

SN - 1542-3565

VL - 21

SP - 1303-1313.e11

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 5

ER -

Serum HBcrAg and Hepatocellular Carcinoma in a Taiwanese Population Seronegative for HBsAg and Anti-HCV

摘要

文獻附註

UN SDG

存取文件

其它文件與鏈接

指紋

引用此